

Saint Kitts and Nevis

Tuberculosis profile

Population 2015

<1 million

| Estimates of TB burden*, 2015 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB) | <0.01 (<0.01–<0.01) | 2.5 (2.1–2.9) |
| Mortality (HIV+TB only) | <0.01 (0–<0.01) | 0.09 (0–0.46) |
| Incidence (includes HIV+TB) | <0.01 (<0.01–<0.01) | 5.1 (4.4–5.9) |
| Incidence (HIV+TB only) | 0 (0–0) | 0.7 (0.54–0.87) |
| Incidence (MDR/RR-TB)** | 0 (0–0) | 0.31 (0.16–0.45) |

Estimated TB incidence by age and sex (thousands)*, 2015

| | 0-14 years | > 14 years | Total |
|---------|------------|---------------------|---------------------|
| Females | 0 (0–0) | <0.01 (0–<0.01) | <0.01 (0–<0.01) |
| Males | 0 (0–0) | <0.01 (<0.01–<0.01) | <0.01 (<0.01–<0.01) |
| Total | 0 (0–0) | <0.01 (<0.01–<0.01) | <0.01 (<0.01–<0.01) |

TB case notifications, 2015

| | |
|--|--|
| Total cases notified | |
| Total new and relapse | |
| - % tested with rapid diagnostics at time of diagnosis | |
| - % with known HIV status | |
| - % pulmonary | |
| - % bacteriologically confirmed among pulmonary | |

Universal health coverage and social protection

| | |
|--|-----------------|
| TB treatment coverage (notified/estimated incidence), 2015 | |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.51 (0.4–0.64) |

TB/HIV care in new and relapse TB patients, 2015

| | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | | |
| - on antiretroviral therapy | | |

| Drug-resistant TB care, 2015 | New cases | Previously treated cases | Total number*** |
|---|----------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | (–) |
| Estimated % of TB cases with MDR/RR-TB | 2.3% (1.4–3.2) | 15% (13–18) | |
| % notified tested for rifampicin resistance | | | |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | |
| Laboratory-confirmed cases | | MDR/RR-TB: , XDR-TB: | |
| Patients started on treatment **** | | MDR/RR-TB: , XDR-TB: | |

Treatment success rate and cohort size

| | Success | Cohort |
|--|---------|--------|
| New cases registered in 2014 | | |
| Previously treated cases registered in 2014 | | |
| HIV-positive TB cases, all types, registered in 2014 | | |
| MDR/RR-TB cases started on second-line treatment in 2013 | | |
| XDR-TB cases started on second-line treatment in 2013 | | |

TB preventive treatment, 2015

| | |
|---|--|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | |

TB financing, 2016

| | |
|------------------------------------|--|
| National TB budget (US\$ millions) | |
|------------------------------------|--|


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB